Bristol-Meyers Squibb Co. is scheduled to hold talks on Wednesday to settle over $500 million in claims of liver-disease as a result of a company-sponsored drug trial for Hepatitis C last year. Bristol received requests for medical costs and damages from 14 people injured or killed during the trial of their latest treatment pill. The company’s new drug was discontinued last August “in the interest of patient safety,” according to company spokespeople after one patient died and several were hospitalized. The company’s latest failure is a blow to its efforts to enter the growing $5 billion market for hepatitis C treatments, an infection which affects 3.2 million Americans and over 150 million people world-wide.

To read the article, click here.